4/18/2024

Janusmed kön och genus

Janusmed kön och genus – Zirabev

Janusmed kön och genus är ett kunskapsstöd som tillhandahåller information om köns- och genusaspekter på läkemedelsbehandling. Kunskapsstödet är avsedd främst för hälso- och sjukvårdspersonal. Texterna är generella och ska inte ses som behandlingsriktlinjer. Det är alltid behandlande läkare som ansvarar för patientens medicinering.

För att komma till startsidan för Janusmed kön och genus och för att göra sökningar klicka här.

Tillbaka till index
C C
C C

Bevacizumab

Bevacizumab

Klass : C

Visa all info

Skriv ut

Kontakta oss

  1. Avastin (bevacizumab). Summary of Product Characteristics. Swedish Medical Products Agency [updated 2019-09-25, cited 2019-10-25].

  2. Huang V, Bergner AL, Halpin C, Merker VL, Sheridan MR, Widemann BC et al. Improvement in Patient-reported Hearing After Treatment With Bevacizumab in People With Neurofibromatosis Type 2. Otol Neurotol. 2018;39(5):632-638.

  3. van Asten F, Michels CTJ, Hoyng CB, van der Wilt GJ, Klevering BJ, Rovers MM et al. The cost-effectiveness of bevacizumab, ranibizumab and aflibercept for the treatment of age-related macular degeneration-A cost-effectiveness analysis from a societal perspective. PLoS One. 2018;13(5):e0197670.

  4. Buscarini E, Botella LM, Geisthoff U, Kjeldsen AD, Mager HJ, Pagella F et al. Safety of thalidomide and bevacizumab in patients with hereditary hemorrhagic telangiectasia. Orphanet J Rare Dis. 2019;14(1):28.

  5. Virgili G, Parravano M, Evans JR, Gordon I, Lucenteforte E. Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis. Cochrane Database Syst Rev. 2017;6(1):CD007419.

  6. Lapid-Gortzak R, Santana NTY, Nieuwendaal CP, Mourits MP, van der Meulen IJE. Topical bevacizumab treatment in aniridia. Int Ophthalmol. 2018;38(4):1741-1746.

  7. Zur KB, Fox E. Bevacizumab chemotherapy for management of pulmonary and laryngotracheal papillomatosis in a child. Laryngoscope. 2017;127(7):1538-1542.

  8. Scott IU, VanVeldhuisen PC, Ip MS, Blodi BA, Oden NL, Awh CC et al. Effect of Bevacizumab vs Aflibercept on Visual Acuity Among Patients With Macular Edema Due to Central Retinal Vein Occlusion: The SCORE2 Randomized Clinical Trial. JAMA. 2017;317(20):2072-2087.

  9. Han K, Peyret T, Marchand M, Quartino A, Gosselin NH, Girish S et al. Population pharmacokinetics of bevacizumab in cancer patients with external validation. Cancer Chemother Pharmacol. 2016;78(2):341-51.

  10. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355(24):2542-50.

  11. Brahmer JR, Dahlberg SE, Gray RJ, Schiller JH, Perry MC, Sandler A et al. Sex differences in outcome with bevacizumab therapy: analysis of patients with advanced-stage non-small cell lung cancer treated with or without bevacizumab in combination with paclitaxel and carboplatin in the Eastern Cooperative Oncology Group Trial 4599. J Thorac Oncol. 2011;6(1):103-8.

  12. Liau CT, Chou WC, Wei KC, Chang CN, Toh CH, Jung SM. Female sex, good performance status, and bevacizumab-induced hypertension associated with survival benefit in Asian patients with recurrent glioblastoma treated with bevacizumab. Asia Pac J Clin Oncol. 2018;14(2):e8-e14.

  13. Krex D, Klink B, Hartmann C, von Deimling A, Pietsch T, Simon M et al. Long-term survival with glioblastoma multiforme. Brain. 2007;130(1):2596-606.

  14. Shinojima N, Kochi M, Hamada J, Nakamura H, Yano S, Makino K et al. The influence of sex and the presence of giant cells on postoperative long-term survival in adult patients with supratentorial glioblastoma multiforme. J Neurosurg. 2004;101(2):219-26.

  15. Plunkett RJ, Lis A, Barone TA, Fronckowiak MD, Greenberg SJ. Hormonal effects on glioblastoma multiforme in the nude rat model. J Neurosurg. 1999;90(6):1072-7.

  16. Seki Y, Suico MA, Uto A, Hisatsune A, Shuto T, Isohama Y et al. The ETS transcription factor MEF is a candidate tumor suppressor gene on the X chromosome. Cancer Res. 2002;62(22):6579-86.

  17. Bilir C, Engin H, Temi YB. Effect of gender on coagulation functions: a study in metastatic colorectal cancer patients treated with bevacizumab, irinotecan, 5-Fluorouracil, and leucovorin. Adv Hematol. 2014;2014(1):473482.

  18. Marmorino F, Rossini D, Lonardi S, Moretto R, Zucchelli G, Aprile G et al. Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies. Ann Oncol. 2019;1(1):1.

  19. Concise (INSIKT). Kalmar: eHälsomyndigheten. 2018 [cited 2019-03-14.]

  1. Avastin (bevacizumab). Summary of Product Characteristics. Swedish Medical Products Agency [updated 2019-09-25, cited 2019-10-25].
  2. Huang V, Bergner AL, Halpin C, Merker VL, Sheridan MR, Widemann BC et al. Improvement in Patient-reported Hearing After Treatment With Bevacizumab in People With Neurofibromatosis Type 2. Otol Neurotol. 2018;39(5):632-638.
  3. van Asten F, Michels CTJ, Hoyng CB, van der Wilt GJ, Klevering BJ, Rovers MM et al. The cost-effectiveness of bevacizumab, ranibizumab and aflibercept for the treatment of age-related macular degeneration-A cost-effectiveness analysis from a societal perspective. PLoS One. 2018;13(5):e0197670.
  4. Buscarini E, Botella LM, Geisthoff U, Kjeldsen AD, Mager HJ, Pagella F et al. Safety of thalidomide and bevacizumab in patients with hereditary hemorrhagic telangiectasia. Orphanet J Rare Dis. 2019;14(1):28.
  5. Virgili G, Parravano M, Evans JR, Gordon I, Lucenteforte E. Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis. Cochrane Database Syst Rev. 2017;6(1):CD007419.
  6. Lapid-Gortzak R, Santana NTY, Nieuwendaal CP, Mourits MP, van der Meulen IJE. Topical bevacizumab treatment in aniridia. Int Ophthalmol. 2018;38(4):1741-1746.
  7. Zur KB, Fox E. Bevacizumab chemotherapy for management of pulmonary and laryngotracheal papillomatosis in a child. Laryngoscope. 2017;127(7):1538-1542.
  8. Scott IU, VanVeldhuisen PC, Ip MS, Blodi BA, Oden NL, Awh CC et al. Effect of Bevacizumab vs Aflibercept on Visual Acuity Among Patients With Macular Edema Due to Central Retinal Vein Occlusion: The SCORE2 Randomized Clinical Trial. JAMA. 2017;317(20):2072-2087.
  9. Han K, Peyret T, Marchand M, Quartino A, Gosselin NH, Girish S et al. Population pharmacokinetics of bevacizumab in cancer patients with external validation. Cancer Chemother Pharmacol. 2016;78(2):341-51.
  10. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355(24):2542-50.
  11. Brahmer JR, Dahlberg SE, Gray RJ, Schiller JH, Perry MC, Sandler A et al. Sex differences in outcome with bevacizumab therapy: analysis of patients with advanced-stage non-small cell lung cancer treated with or without bevacizumab in combination with paclitaxel and carboplatin in the Eastern Cooperative Oncology Group Trial 4599. J Thorac Oncol. 2011;6(1):103-8.
  12. Liau CT, Chou WC, Wei KC, Chang CN, Toh CH, Jung SM. Female sex, good performance status, and bevacizumab-induced hypertension associated with survival benefit in Asian patients with recurrent glioblastoma treated with bevacizumab. Asia Pac J Clin Oncol. 2018;14(2):e8-e14.
  13. Krex D, Klink B, Hartmann C, von Deimling A, Pietsch T, Simon M et al. Long-term survival with glioblastoma multiforme. Brain. 2007;130(1):2596-606.
  14. Shinojima N, Kochi M, Hamada J, Nakamura H, Yano S, Makino K et al. The influence of sex and the presence of giant cells on postoperative long-term survival in adult patients with supratentorial glioblastoma multiforme. J Neurosurg. 2004;101(2):219-26.
  15. Plunkett RJ, Lis A, Barone TA, Fronckowiak MD, Greenberg SJ. Hormonal effects on glioblastoma multiforme in the nude rat model. J Neurosurg. 1999;90(6):1072-7.
  16. Seki Y, Suico MA, Uto A, Hisatsune A, Shuto T, Isohama Y et al. The ETS transcription factor MEF is a candidate tumor suppressor gene on the X chromosome. Cancer Res. 2002;62(22):6579-86.
  17. Bilir C, Engin H, Temi YB. Effect of gender on coagulation functions: a study in metastatic colorectal cancer patients treated with bevacizumab, irinotecan, 5-Fluorouracil, and leucovorin. Adv Hematol. 2014;2014(1):473482.
  18. Marmorino F, Rossini D, Lonardi S, Moretto R, Zucchelli G, Aprile G et al. Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies. Ann Oncol. 2019;1(1):1.
  19. Concise (INSIKT). Kalmar: eHälsomyndigheten. 2018 [cited 2019-03-14.]